Hua Medicine (Shanghai) Management
Management criteria checks 3/4
Hua Medicine (Shanghai)'s CEO is Li Chen, appointed in Jun 2010, has a tenure of 13.92 years. total yearly compensation is CN¥22.63M, comprised of 22.3% salary and 77.7% bonuses, including company stock and options. directly owns 3.97% of the company’s shares, worth HK$61.75M. The average tenure of the management team and the board of directors is 4.3 years and 5.7 years respectively.
Key information
Li Chen
Chief executive officer
CN¥22.6m
Total compensation
| CEO salary percentage | 22.3% |
| CEO tenure | 13.9yrs |
| CEO ownership | 4.0% |
| Management average tenure | 4.3yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?
Nov 17
Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects
Aug 28We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth
Jan 06We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow
Aug 02Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Apr 22Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Sep 23We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn
Jun 24Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Mar 22Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook
Feb 21Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year
Jan 25
Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business
Dec 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -CN¥211m |
| Sep 30 2023 | n/a | n/a | -CN¥200m |
| Jun 30 2023 | n/a | n/a | -CN¥189m |
| Mar 31 2023 | n/a | n/a | -CN¥196m |
| Dec 31 2022 | CN¥23m | CN¥5m | -CN¥204m |
| Sep 30 2022 | n/a | n/a | -CN¥234m |
| Jun 30 2022 | n/a | n/a | -CN¥265m |
| Mar 31 2022 | n/a | n/a | -CN¥295m |
| Dec 31 2021 | CN¥24m | CN¥5m | -CN¥326m |
| Sep 30 2021 | n/a | n/a | -CN¥355m |
| Jun 30 2021 | n/a | n/a | -CN¥385m |
| Mar 31 2021 | n/a | n/a | -CN¥389m |
| Dec 31 2020 | CN¥28m | CN¥5m | -CN¥393m |
| Sep 30 2020 | n/a | n/a | -CN¥378m |
| Jun 30 2020 | n/a | n/a | -CN¥363m |
| Mar 31 2020 | n/a | n/a | -CN¥394m |
| Dec 31 2019 | CN¥28m | CN¥4m | -CN¥425m |
| Sep 30 2019 | n/a | n/a | -CN¥1b |
| Jun 30 2019 | n/a | n/a | -CN¥2b |
| Mar 31 2019 | n/a | n/a | -CN¥3b |
| Dec 31 2018 | CN¥12m | CN¥2m | -CN¥4b |
| Sep 30 2018 | n/a | n/a | -CN¥3b |
| Jun 30 2018 | n/a | n/a | -CN¥2b |
| Mar 31 2018 | n/a | n/a | -CN¥440m |
| Dec 31 2017 | CN¥4m | CN¥3m | -CN¥273m |
Compensation vs Market: Li's total compensation ($USD3.13M) is above average for companies of similar size in the Hong Kong market ($USD357.59K).
Compensation vs Earnings: Li's compensation has been consistent with company performance over the past year.
CEO
Li Chen (60 yo)
13.9yrs
Tenure
CN¥22,630,000
Compensation
Dr. Li Chen, Ph.D. is the Co-Founder of Hua Medicine (Shanghai) Ltd. and served as its Chief Scientific Officer until 2022 and served as its President until May 19, 2016 and has been its Chief Executive Of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 13.9yrs | CN¥22.63m | 3.97% CN¥ 61.8m | |
| Executive VP | 1.3yrs | CN¥6.03m | 0.87% CN¥ 13.5m | |
| Vice President of Operation Department | 3yrs | no data | no data | |
| Director of Corporate Finance | no data | no data | no data | |
| CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA | 4.3yrs | no data | no data | |
| Chief Scientific Officer | 1.4yrs | no data | no data | |
| Head of IR | no data | no data | no data | |
| VP and Head of Commercial Strategy & Marketing | 5.8yrs | no data | no data | |
| Senior VP of Pharma Development & Chief Medical Officer – China and Executive Director | 6.1yrs | no data | no data | |
| VP of Quality Assurance & Chief Quality Officer | less than a year | no data | no data | |
| Company Secretary | 4.4yrs | no data | no data |
4.3yrs
Average Tenure
53yo
Average Age
Experienced Management: 2552's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 13.9yrs | CN¥22.63m | 3.97% CN¥ 61.8m | |
| Executive VP | 6yrs | CN¥6.03m | 0.87% CN¥ 13.5m | |
| Senior VP of Pharma Development & Chief Medical Officer – China and Executive Director | less than a year | no data | no data | |
| Non-Executive Chairman | 14.1yrs | no data | 0.015% CN¥ 238.6k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 5.7yrs | CN¥450.00k | 0.0024% CN¥ 38.1k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-executive Director | 5.7yrs | CN¥540.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 1.3yrs | no data | no data | |
| Non-Executive Director | less than a year | no data | no data |
5.7yrs
Average Tenure
62yo
Average Age
Experienced Board: 2552's board of directors are considered experienced (5.7 years average tenure).